A Single-center, Randomized, Double-blind, Active-controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of 26-valent Pneumococcal Conjugate Vaccine in People Aged 2 Months and Older
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Pneumococcal conjugate 26 valent vaccine Beijing Zhifei Lvzhu Biopharmaceutical (Primary) ; 13-Valent pneumococcal conjugate vaccine; Pneumococcal polysaccharide 23 valent vaccine Beijing Zhifei Lvzhu Biopharmaceutical
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Beijing Zhifei Lvzhu Biopharmaceutical
Most Recent Events
- 27 Nov 2024 New trial record